Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy

Journal of Viral Hepatitis

Volumn 18, Issue 2, 2011, Pages 119-128

  Chen, T M ^a,b   Huang, P T ^a   Wen, C F ^a   Tung, J N ^a   Chow, K C ^c   Chen, Y P ^a,c  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

hepatitis C; individualized therapy; NS5A; peginterferon; PKR binding domain

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN KINASE; RIBAVIRIN; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; ANEMIA; ANOREXIA; APHTHOUS ULCER; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; COUGHING; DEPRESSION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEVER; HAIR LOSS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; EIF-2 KINASE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 78751511682     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01287.x     Document Type: Article

References (33)

1. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345 (1): 41-52.
2. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358 (9286): 958-965.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
5. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22 (5): 615-633.
6. Poordad F, Reddy KR, Martin P,. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008; 46 (1): 78-84.
7. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16 (2): 75-90.
8. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47 (1): 43-50.
9. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47 (10): 1260-1269.
10. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47 (6): 1884-1893.
11. Nousbaum J, Polyak SJ, Ray SC, et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000; 74 (19): 9028-9038.
12. Gale MJ Jr, Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230 (2): 217-227.
13. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96 (1): 224-230.
14. Pascu M, Martus P, HoÂhne M, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5AISDR: a meta-analysis focused on geographical differences. Gut 2004; 53 (9): 1345-1351.
15. Gale M Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18 (9): 5208-5218.
16. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 1: 15-20.
17. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43 (5): 954-960.
18. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87 (24): 9524-9528.
19. Muñoz de Rueda P, Casado J, Patõn R, et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol 2008; 82 (13): 6644-6653.
20. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123 (4): 1061-1069.
21. Yen YH, Hung CH, Hu TH, et al. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008; 27 (1): 72-79.
22. Okanoue T, Itoh Y, Hashimoto H, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009; 44 (9): 952-963.
23. Akuta N, Suzuki F, Hirakawa M, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81 (3): 452-458.
24. Hsu CS, Liu CH, Liu CJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 2009; 14 (1): 45-54.
25. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46 (3): 403-410.
26. Akuta N, Suzuki F, Kawamura Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007; 79 (11): 1686-1695. (Pubitemid 47479887)
27. Schiappa DA, Mittal C, Brown JA, Mika BP,. Relationship of hepatitis C genotype 1 NS5A sequence mutations to early phase viral kinetics and interferon effectiveness. J Infect Dis 2002; 185 (7): 868-877.
28. Sarrazin C, Berg T, Lee JH, et al. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J Infect Dis 2000; 181 (2): 432-441. (Pubitemid 30131807)
29. Polyak SJ, Paschal DM, McArdle S, Gale MJ Jr, Moradpour D, Gretch DR,. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999; 29 (4): 1262-1271.
30. Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR,. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 1999; 117 (5): 1187-1197.
31. Durante Mangoni E, Forton DM, Ruggiero G, Karayiannis P,. Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations. J Med Virol 2003; 70 (1): 62-73.
32. Maekawa S, Enomoto N,. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol 2009; 44 (10): 1009-1015.
33. Torres-Puente M, Cuevas JM, Jiménez-Hernández N, et al. Genetic variability in hepatitis C virus and its role in antiviral treatment response. J Viral Hepat 2008; 15 (3): 188-199.